S-1: OneMedNet Files for Resale of Over 11 Million Shares

OneMedNet Corporation has filed a registration statement with the SEC to permit the resale of up to 11,680,535 shares of its common stock by selling stockholders.

Summary

• OneMedNet Corporation has filed an S-1 registration statement with the SEC to allow for the resale of up to 11,680,535 shares of its common stock.
• These shares are held by various selling stockholders, including Yorkville, Dr. Thomas Kosasa, and Dr. Jeffrey Yu.
• The filing details the terms of a Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing OneMedNet to sell up to $25 million in common stock.
• It also outlines additional investments made by Dr. Kosasa and Dr. Yu through subscription agreements.
• The company is currently listed on the Nasdaq Capital Market under the symbol ONMD.
• The filing highlights significant risks, including the company's history of operating losses, substantial doubt about its ability to continue as a going concern, and Nasdaq's non-compliance notice regarding the minimum bid price requirement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the company's ongoing financial struggles, going concern issues, and Nasdaq listing non-compliance, despite some positive developments like insider investments and a SEPA agreement.

Positives

• The company has secured a Standby Equity Purchase Agreement (SEPA) with Yorkville, providing potential access to up to $25 million in capital.
• Key insiders, including Dr. Thomas Kosasa and Dr. Jeffrey Yu, have made significant additional investments in the company.
• The company is actively working to regain compliance with Nasdaq's minimum bid price requirement, indicating a commitment to maintaining its listing.
• OneMedNet is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (iRWDTM), a growing market.
• The company has a federated network of 2,130 healthcare sites, providing access to extensive patient data.

Negatives

• The company has a history of operating losses and an accumulated deficit of $104.4 million as of December 31, 2025.
• The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• OneMedNet received a notice from Nasdaq on April 14, 2026, indicating non-compliance with the $1.00 minimum bid price requirement for continued listing.
• The company is an emerging growth company and a smaller reporting company, which may make its stock less attractive to investors.
• The filing indicates that management does not believe current cash and cash equivalents are sufficient to meet foreseeable cash needs for at least the next 12 months.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's common stock may be subject to extreme volatility.
• Failure to maintain listing on the Nasdaq Capital Market could adversely affect the stock price and liquidity.
• Principal stockholders have significant influence over board elections and corporate actions.
• The company could be subject to securities class action litigation.
• Lack of research coverage or inaccurate research from analysts could negatively impact the stock price.
• The company does not expect to pay dividends in the foreseeable future.
• Future sales of substantial amounts of common stock could adversely affect the market price.
• The securities being offered represent a substantial percentage of outstanding common stock, potentially impacting market price.
• The company has a history of operating losses and may never achieve profitability.
• The company may encounter difficulties in managing its growth.
• The Real World Data and Real World Evidence market is highly competitive.
• The company depends on key employees, and their loss could harm operations.
• Cybersecurity breaches or other disruptions could adversely affect the company.
• Failure to adequately protect intellectual property could harm business prospects.
• Non-compliance with healthcare industry regulations could lead to increased costs and penalties.
• The company's collection, use, and disclosure of personal information are subject to privacy regulations.
• The company is subject to risks related to holding bitcoin, which is highly volatile.
• Management has limited experience operating a public company.
• The company has incurred significant increased expenses and administrative burdens as a public company.
• Material weaknesses in internal control over financial reporting could lead to inaccurate financial reporting.
• The company's capital-intensive business model may hinder its ability to raise additional capital on attractive terms.

Future Outlook

The company's future outlook is heavily dependent on its ability to secure additional financing and regain compliance with Nasdaq listing requirements. Management is actively seeking to raise capital through debt and equity offerings to fund operations and capital requirements.

Management Comments

• The company intends to continue to actively monitor the bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Bid Price Rule.
• Management does not believe that cash and cash equivalents are sufficient to meet our foreseeable cash needs for at least the next 12 months.
• Management plans to raise cash for operations through debt and equity offerings.

Industry Context

StockSavvy.ai notes that OneMedNet operates in the growing Real World Data (RWD) and Real World Evidence (RWE) market, which is driven by the life sciences industry's need for data to support drug development, regulatory approvals, and market strategies. The increasing adoption of RWD/RWE by regulatory bodies like the FDA highlights the importance of companies like OneMedNet. However, the competitive landscape is intense, and the company faces challenges related to its financial position and Nasdaq listing compliance.

Legal Proceedings

• ARC Group Limited and ARC Opportunity Fund Limited filed a complaint alleging breach of contracts and seeking specific performance or damages. The company believes the claim is overstated and intends to defend itself vigorously. ARC voluntarily dismissed the complaint without prejudice on March 19, 2026.

Related Party Transactions

• PIPE Notes and Warrants: $1.0 million of PIPE Notes were with related party investors, including Mr. Green, Dr. Yu, and Dr. Kosasa. These were converted into shares of Common Stock.
• Convertible Promissory Notes and Warrants: $12.3 million of Convertible Promissory Notes were issued to related party investors.
• Shareholder Loans: From April 2023 to February 2024, the company received $0.7 million in non-convertible shareholder loans from related parties, and $1.6 million in convertible shareholder loans from related parties.
• Loan Extensions: The company assumed Data Knights liabilities, including loan extensions to related parties.
• June 2025 Kosasa and Yu Investments: Dr. Thomas Kosasa and Dr. Jeffrey Yu made investments totaling $1.2 million and $0.7 million respectively, through subscription agreements.
• Additional Investments: Dr. Thomas Kosasa and Dr. Jeffrey Yu made several additional investments through subscription agreements in 2025 and 2026.
• Accounting Services: The company incurs expenses for accounting services from a firm majority-owned by the CFO.
• Software Development Services: The company incurs expenses for software development services from a company wholly owned by the CTO.

Stakeholder Impact

• Shareholders: Potential dilution from future equity issuances, risk of stock price decline due to resale of shares, and risk of delisting from Nasdaq.
• Creditors: The company's going concern issues and history of losses may impact the ability to repay debts.
• Employees: Potential impact on morale and job security due to financial instability and the need for cost management.
• Customers: Continued service delivery is dependent on the company's ability to secure financing and manage operations.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement.
• Secure additional financing through debt and equity offerings.
• Continue to develop and market its iRWDTM solutions.
• Address material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

While the company operates in a growing market and has secured some insider investment and a SEPA, the significant financial challenges, including recurring losses, going concern issues, and Nasdaq non-compliance, present substantial risks. The potential for dilution from the SEPA and the resale of a large number of shares also weighs on the stock. A 'hold' recommendation reflects a cautious approach, awaiting clearer signs of financial stabilization and Nasdaq listing compliance before considering a more positive stance.

Keywords

OneMedNet, ONMD, SEC Filing, S-1, Resale of Shares, Standby Equity Purchase Agreement, SEPA, Yorkville, Healthcare Software, Real World Data, iRWDTM, Nasdaq Compliance, Going Concern, Capital Raise